Atjaunināt sīkdatņu piekrišanu

Advances in Nanomedicine for the Delivery of Therapeutic Nucleic Acids [Hardback]

, (Ambedkar Center for Biomedical Researc), (Professor, Department of Biotechnology, Central University of Rajasthan, Ajmer, India; Professor (Adjunct), Department of Biomedical Science, Maharaja Surajmal Brij University, Bharatpur, India.)
  • Formāts: Hardback, 256 pages, height x width: 229x152 mm, weight: 540 g
  • Izdošanas datums: 06-Apr-2017
  • Izdevniecība: Woodhead Publishing Ltd
  • ISBN-10: 0081005571
  • ISBN-13: 9780081005576
Citas grāmatas par šo tēmu:
  • Hardback
  • Cena: 223,78 €
  • Grāmatu piegādes laiks ir 3-4 nedēļas, ja grāmata ir uz vietas izdevniecības noliktavā. Ja izdevējam nepieciešams publicēt jaunu tirāžu, grāmatas piegāde var aizkavēties.
  • Daudzums:
  • Ielikt grozā
  • Piegādes laiks - 4-6 nedēļas
  • Pievienot vēlmju sarakstam
Advances in Nanomedicine for the Delivery of Therapeutic Nucleic AcidsPalielināt
  • Formāts: Hardback, 256 pages, height x width: 229x152 mm, weight: 540 g
  • Izdošanas datums: 06-Apr-2017
  • Izdevniecība: Woodhead Publishing Ltd
  • ISBN-10: 0081005571
  • ISBN-13: 9780081005576
Citas grāmatas par šo tēmu:
Permanent link: https://www.kriso.lv/db/9780081005576.html
Keywords:

Advances in Nanomedicine for the Delivery of Therapeutic Nucleic Acids addresses several issues related to safe and effective delivery of nucleic acids (NAs) using nanoparticles. A further emphasis would be laid on the mechanism of delivery of NAs, the barriers encountered and the strategies adapted to combat them. An exhaustive account of the advantages as well shortcomings of all the delivery vectors being employed in delivery of various NAs will be provided. On final note the regulatory aspects of nanoparticles mediated NA would be discussed, with focus on their clinical relevance.

The design and development of nucleic acid-based therapeutics for the treatment of diseases arising from genetic abnormalities has made significant progress over the past few years. NAs have been widely explored for the treatment of cancer and infectious diseases or to block cell proliferation and thereby caused diseases. Advances in synthetic oligonucleotide chemistry resulted in synthesis of NAs that are relatively stable in in vivo environments. However, cellular targeting and intracellular delivery of NAs still remains a challenge. Further development of NA-based therapeutics depends on the progress of safe and effective carriers for systemic administration. Nanomedicine has facilitated availability of vectors with diminished cytotoxicity and enhanced efficacy which are rapidly emerging as systems of choice. These vectors protect NAs from enzymatic degradation by forming condensed complexes along with targeted tissue and cellular delivery. During the past few years, a myriad reports have appeared reporting delivery of NAs mediated by nanoparticles. This book will provide an overview of nanoparticles being employed in the in vitro and in vivo delivery of therapeutically relevant NAs like DNA, siRNA, LNA, PNA, etc.

  • Provides a complete overview of the applicatiosn of nanomedicine in the delivery of nucleic acids, from characterization of nanoparticles, to in vitro and in vivo studies
  • Discusses delivery issues of less well explored nucleic acids, like PNAs, Ribozymes, DNAzymes, etc.
  • Summarizes the current state of research in nucleic acid delivery and underscores the future of nanomedicine in this field

Papildus informācija

A unique exploration of the applications of nanomedicine for the delivery of nucleic acid-based therapeutics
List of contributors
ix
Foreword xi
Preface xiii
Acknowledgments xv
1 Nanomedicine for delivery of therapeutic molecules
1(12)
Surendra Nimesh
Nidhi Gupta
1.1 Introduction
1(2)
1.2 Properties of nanoparticles
3(2)
1.3 Polymeric nanoparticles
5(1)
1.4 Nanoparticle-based strategies for overcoming in vitro and in vivo barriers
5(3)
1.5 Book compilation
8(5)
References
8(5)
2 Nanoparticles as nucleic acid delivery vectors
13(30)
Ashok Kumar Sharma
Lokesh Gupta
Umesh Gupta
2.1 Introduction
13(4)
2.2 Challenges and barriers to the nucleic acid delivery
17(2)
2.3 Vectors in nucleic acid delivery
19(2)
2.4 Nanoparticles as nonviral nucleic acid delivery vectors
21(13)
2.5 Conclusion and future prospects
34(9)
References
35(8)
3 Methods for characterization of nanoparticles
43(16)
Ajeet Kumar
Chandra Kumar Dixit
3.1 Introduction and challenges in nanoparticle characterization
43(1)
3.2 Techniques and approaches to nanoparticle characterization
44(3)
3.3 Stability evaluation of nanoparticles
47(5)
3.4 Sterility assessment of nanoparticles
52(7)
References
54(5)
4 Nanoparticles for DNA delivery
59(24)
Manohar Mahato
Ashwani Kumar Sharma
Pradeep Kumar
4.1 Introduction
59(3)
4.2 Low molecular weight linear polyethylenimine
62(5)
4.3 High molecular weight linear polyethylenimine
67(1)
4.4 Low molecular weight branched polyethylenimine
68(6)
4.5 High molecular weight branched polyethylenimine
74(9)
Acknowledgments
75(1)
References
76(7)
5 Nanoparticles for siRNA-mediated gene silencing
83(30)
Nikita Sharma
R. Mankamna Kumari
Geeta Arya
Surendra Nimesh
Ramesh Chandra
5.1 Introduction
83(1)
5.2 Chitosan
84(4)
5.3 Polyethylenimine
88(5)
5.4 Poly-L-lysine
93(3)
5.5 Dendrimers
96(5)
5.6 Cyclodextrins
101(2)
5.7 Poly(lactic-co-glycolic) acid
103(10)
References
106(7)
6 Nanoparticles for locked nucleic acid delivery
113(22)
R. Mankamna Kumari
Nidhi Gupta
Surendra Nimesh
6.1 Introduction
113(1)
6.2 Locked nucleic acids: structure
114(1)
6.3 Locked nucleic acids: hybridization and conformation properties
114(1)
6.4 Serum stability and nuclease resistance
115(1)
6.5 Delivery and toxicity
116(1)
6.6 Therapeutic applications of locked nucleic acids
117(5)
6.7 Nanoparticle-mediated delivery of locked nucleic acid and locked nucleic acid-modified oligonucleotides
122(7)
6.8 Conclusion and future prospects
129(6)
References
130(5)
7 Nanoparticles for ribozymes delivery
135(16)
Shivangi Goyal
Nidhi Gupta
Ramesh Chandra
7.1 Introduction
135(1)
7.2 Types of ribozymes
136(3)
7.3 Ribozymes and their limitations
139(1)
7.4 Selection of the target gene
140(1)
7.5 Stability of ribozymes
141(1)
7.6 Delivery of ribozymes
141(3)
7.7 Applications of RNA nanoparticles emphasizing ribozymes
144(2)
7.8 Conclusion and future prospects
146(5)
References
147(4)
8 Nanoparticles for DNAzymes delivery
151(14)
Shivangi Goyal
Nidhi Gupta
Ramesh Chandra
8.1 Introduction
151(1)
8.2 DNAzymes
152(1)
8.3 The 10--23 DNAzymes
153(1)
8.4 The 8--17 DNAzymes
154(1)
8.5 Mechanism of DNAzymes
154(1)
8.6 Advantages of DNAzymes
155(1)
8.7 Stability of DNAzymes
155(1)
8.8 Application of DNAzymes
156(1)
8.9 DNAzyme delivery via metallic and polymeric nanoparticles
156(5)
8.10 Conclusion and future prospects
161(4)
References
162(3)
9 Pharmacokinetics and biodistribution of the nanoparticles
165(22)
Kaisar Raza
Pramod Kumar
Nitesh Kumar
Ruchi Malik
9.1 Introduction
165(7)
9.2 Pharmacokinetics of nanoparticles
172(7)
9.3 Generalized pharmacokinetic profile of various nanoparticles
179(2)
9.4 Challenges and future prospects
181(1)
9.5 Conclusions
181(6)
References
181(6)
10 Nanotoxicology: evaluation of toxicity potential of nanoparticles
187(16)
Sreemoyee Chatterjee
R. Mankamna Kumari
Surendra Nimesh
10.1 Introduction
187(2)
10.2 Size of nanoparticles
189(1)
10.3 Dose-dependent toxicity
189(1)
10.4 Nondosage-dependent actions/route
190(1)
10.5 Surface area-dependent toxicity
190(1)
10.6 Concentration-dependent toxicity
191(1)
10.7 Particle chemistry and crystalline structure-dependent toxicity
191(1)
10.8 Aspect ratio-dependent toxicity
192(1)
10.9 Surface coating and functions attributed
193(2)
10.10 Risk management of nanotechnology-specific aspects
195(2)
10.11 Conclusion and future prospects
197(6)
References
199(4)
11 Regulatory aspects of nanoparticulate mediated nucleic acid delivery systems
203(16)
Nikita Sharma
Surendra Nimesh
11.1 Introduction
203(1)
11.2 Issues related with nanoparticle mediated nucleic acid delivery systems
203(2)
11.3 Current approaches for regulating pharmaceutical nanoparticles
205(14)
References
215(4)
12 Clinical studies and future prospects
219(14)
R. Mankamna Kumari
Nikita Sharma
Surendra Nimesh
12.1 Introduction
219(1)
12.2 Regulatory pathways in the process of clinical trials
220(1)
12.3 Barriers in the progress of clinical trials
221(1)
12.4 Ethical concerns in clinical trials
222(1)
12.5 Nanotherapeutics in clinical trials
223(5)
12.6 Conclusion
228(5)
References
228(5)
Index 233
Dr. Surendra Nimesh did PhD in nanotechnology from Dr. B.R. Ambedkar Center for Biomedical Science Research, University of Delhi and CSIR-Institute of Genomics and Integrative Biology, Delhi, India. He did postdoctorate at Ecole Polytechnique of Montreal, Montreal; Clinical Research Institute of Montreal, Montreal and Health Canada, Ottawa, Canada. He has published several research and review articles and authored/coauthored seven books that includes two Elsevier books: The Design and Development of Novel Drugs and Vaccines (2021) and Gene Therapy: Potential Applications of Nanotechnology (2013). He is an internationally recognized expert of nanotechnology for biological applications with specialization in drug and gene delivery. Dr. Nidhi Gupta received PhD degree in virology from the National Institute of Immunology and Jawaharlal Nehru University, New Delhi, India. She did doctoral research at Clinical Research Institute of Montreal, Montreal, and McGill University, Montreal, Canada. She has several research and review articles to her credit along with three authored/coauthored books. Her field of interest includes catalytic nucleic acids, siRNA, antisense, and nanomedicine.